Stockscreener 앱 받기
16.40
2.09%
-0.35
전일 마감가:
$16.75
열려 있는:
$16.77
하루 거래량:
832.64K
Relative Volume:
0.76
시가총액:
$1.00B
수익:
$13.73M
순이익/손실:
$-114.48M
주가수익비율:
-8.9043
EPS:
-1.8418
순현금흐름:
$-78.49M
1주 성능:
+5.53%
1개월 성능:
+24.71%
6개월 성능:
+15.82%
1년 성능:
-35.96%
1일 변동 폭
$15.97
$16.83
1주일 범위
$15.22
$16.91
52주 변동 폭
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
16.40 | 1.00B | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2026-04-15 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-10 | 개시 | Stifel | Buy |
| 2025-09-10 | 개시 | Truist | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings - Stock Titan
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? - Yahoo Finance
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth IndexesWhat's Changed - simplywall.st
Avoiding Lag: Real-Time Signals in (JANX) Movement - Stock Traders Daily
Janux Therapeutics Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises 6%Dividend Cut Risk - dars.gov.et
Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? - Yahoo Finance
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Discipline and Rules-Based Execution in JANX Response - Stock Traders Daily
JANX Forecast — Price Target — Prediction for 2027 - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX) - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (BX:JANX) - TradingView
Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26 - Moomoo
Form 8K Janux Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Janux Therapeutics announces departure of chief medical officer By Investing.com - Investing.com Australia
Janux Therapeutics Announces Departure of Chief Medical Officer - TipRanks
Janux Therapeutics announces departure of chief medical officer - Investing.com
CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search - Stock Titan
JANX Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Clinical ProgressAnalyst Coverage Count - dars.gov.et
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Janux Therapeutics Inc (JANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics Inc (JANX) Institutional Confidence - TradingKey
Top Cybin (HELP) Competitors 2026 - MarketBeat
Janux Therapeutics (JANX) Holds Near Support Amid Quiet Trading SessionWeekly Profile - dars.gov.et
Behavioral Patterns of JANX and Institutional Flows - Stock Traders Daily
Janux Therapeutics Reports Results of 2026 Annual Meeting - The Globe and Mail
Janux Therapeutics (JANX) details RSU and stock option grants to RA Capital–linked entities - Stock Titan
Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital - Stock Titan
Janux Therapeutics (JANX) awards director RSUs and 15,500 options - Stock Titan
Janux Therapeutics (JANX) director awarded RSUs and stock options - Stock Titan
Director at Janux Therapeutics (JANX) gets new RSUs and stock options - Stock Titan
Shareholders back Janux Therapeutics (NASDAQ: JANX) board and pay - Stock Titan
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):